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Summary: The concentrations of laminin, a high molecular weight non-collagenous glycoprotein of basement
membranes, and of the N-terminal propeptide of type III procollagen were determined in the senim of the
liver outflow vascular region (hepatic vein) and of a peripheral vein (cubital vein) in patients with chronic
liver diseases (fibrosis, cirrhosis, unspecified histology; n = 173), in order to determine their secretion rates
from the injured livers. The mean levels of laminin (1.84 kU/1) and of procollagen peptide (28.0 g/l) in
hepatic vein were significantly higher (about 9.5% at p < 0.02, and 37% at p < 0.001, respectively) than
those in the periphery (1.68 kU/1 and 20.4 g/l, respectively). In chronic liver diseases, however, laminin and
procollagen peptide concentrations in the hepatic vein were lower than or equal to those in the cubital vein
in 18% and 27% of patients, respectively. The highest regional differences of the concentrations were noted
in cirrhotic sübjects. The seruin levels of laminin (rs 0.93) and of procollagen peptide (rs 0.73) in hepatic and
in cubital vein are highly positively correlated (p < 0.001), but the levels of procollagen peptide in hepatic
vein are only weakly but still significantly statistically related with those of laminin (rs 0.446, p < 0.001).
Similarly, the hepatic-cubital venous concentration differences of both proteins are weakly (rs 0.312) but
significantly (p < 0.001) correlated. On the basis of several assumptions we estimated secretion rates from
the livers of 120 U · min"1 för laminin, and 5.7 g · min"1 for procollagen peptide. These data support the
view that the chronically injured human liver is highly active in producing serum laminin and procollagen
peptide, which are measured in elevated concentrations in the senim of liver fibrotic and cirrhotic sübjects.
The resülts point to a high turnoVer of these connective tissue-derived proteins in the circulation.
is accomplished by a stimulated production in various
Fibrosis, a inain histological featüre of liver eirrhosis, parenchymal and non-parenchymal types of liver
is characterized biochemically by several fold in- cells, but the mechanisms of enhanced synthesis are
creases of the ainounts and changes of the molecular only pporly understood (2). Along with the develop-
composition of various types of eollagens ( , III, ment of liver fibrosis, the concentrations of some
IV, V, VI), noncollagenous (structural) glycoproteins connective tissue-derived proteins or their cleavage
(fibrpnectin, laminin), proteoglycans (heparan sul- products increase in serum, an observation which has
phate, chondroitiü sulphate, dennatan sulphate), and been exploited for clinical chemical diagnosis and
glycosaminoglycans (hyaluronic acid) iti the extracel- follow-up of fibrogenesis (3, 4). Among these para-
lular space of the liver tissue (1). Their accumulation .meters, the determination of the concentration of the
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aininoterminal propeptide of type III procollagen has
found wide clinical application in the monitoring of
patients with chronic liver diseases, who risk develop-
ment of fibrosis and cirrhosis (3-6). The level of
procollagen peptide in serum has been shown to be
closely correlated with the activity of the fibrogenic
process (7 — 14) and the extent of the fibrotic transfor-
mation (7, 15—17) of chronically injured liver. Re-
cently, elevated concentrations of Iaminin, a high
molecular weight (Mr ~ l · l O6) noncollagenous
glycoprotein constituent of basement membranes (18,
19), have been measured in the sera of fibrotic and
cirrhotic liver patients; the extent of the elevation was
reported to be correlated with the severity of organ
fibrosis (17, 20 — 24) and the degree of portal hyper-
tension (21 — 24). The mechanism of the elevation of
the connective tissue proteins in serum of fibrotic
liver patients is not clear. It may be due to enhanced
synthesis and fractional secretion by the producing
cell types of the liver, stimulated break-down and
discharge into the circulation of intercellularly de-
posited matrix proteins, or by reduced clearance of
circulating connective tissue proteins originating
from nonhepatic sources. In the following study we
attempted to define the production of serum procolla-
gen peptide and Iaminin in fibrotic livers by measur-
ing their concentrations selectively in the liver outflow
and comparing them with the respective levels in
peripheral venous regions. Based on several as-
sumptions, we tried to estimate the order of magni-
tude of the contribution of fibrotic livers to the serum
pool of Iaminin and procollagen peptide, respectively.
Materials and Methods
Patients
Hospitalized patients with chronic liver diseases (n = 173) of
various aetiologies (50% chronic alcohol consumption, 22%
posthepatitis B, 28% miscellaneous and unknown) were subdi-
vided into those with histologically verified fibrosis (n = 55)
and cirrhosis (n = 41), and those (n = 77) with unspecified
histology where a liver biopsy specimen was not available. The
hepatic vein of all patients was catheterized for measurement
of portal vein pressure (25). Patients were informed äbout the
procedure and gave their consent. Venous catheterization was
performed with a Swan-Ganz balloon catheter starting froin
the right femoral vein using Seldinger's technique (26). The tip
of the catheter was introduced into the right hepatic vein under
fluoroscopic control.
Specimen collection
Blood was aspirated simultaneously from the hepatic vein and
from the periphery (cubital vein). All patients were in an over-
night fasting state. After allowing the blood to clot for l h at
room temperature serum was prepared by centrifugation and
stored at — 70 °C for a maximum of one month before the
assays were performed.
Assay of N-terminal propeptide of type III procol-
lagen
The propeptide was analysed in various dilutions (1:5, l :20,
l: 50) of serum by a radioimmunoassay for the aminotenninal
propeptide of type III procollagen (Behring-Hoechst, Frank-
furt, FRG). Details of the assay have been described previously
(27—29). The within-run coefficient of Variation (CV) was
4.9% (x = 12 ^; n = 40); the day-to-day CV was 7.2% (x
= 5.0 g/l; n = 36). The upper limit'of the reference ränge of
procollagen peptide in serum is ^ 12 g/l (29).
Assay of Iaminin
The concentration of the glycoprotein was determiiied with a
competitive radioimmunoassay (Behring-Hoechst, Frankfurt,
FRG), details of which are reported elsewhere (30). The änti-
body is directed against antigenic determinants of the pepsin^
resistant fragment Pl of Iaminin (31). The coefficients of Varia-
tion of the within-mn and day-to-däy imprecisions were 3.1%
and 4.9% (x = 2.0 kU/1), respectively. The inaccuracy ranged
from -12% to + 11%. During storage at -20 °C no signifi-
cant loss of Iaminin was npted. According to the mänufacturer
of the test reagents, the concentrations of Iaminin are gjven in
arbitrary kU/1 because an international Standard of Iaminin is
not available; l U is deflned äs the mean quantity of Iaminin
per ml serum in a group of obviously healthy persons and
corresponds to about 0.230 g (31). The reference ränge of
Iaminin in serum (2.5 — 97.5 percentile) was detennined pre-
viously to be 0.81-1.43 kU/1 (median 1.04 kU/1) (21).
Estimation of liver production rates of Iaminin and
propeptide of type III procoljagen
Synthesis and/or secretion rates of the respective connective
tissue proteins in the liver were calculated from the difference
between the antigen concentrations in the liver outflow vascular
region (vena hepatica) and in a peripheral vein (veiaa cubitalis),
based on the following assumptions:
i) a blood perfusion rate of the liver of 1.50 l/min per 1.73 m2
body surface area (32),
ii) liver inflow concentrations of the proteins corresponding to
those ineasured in the cubital vein,
iii) identical concentrations of the respective proteins in portal
vein (providing 70 to 75% of total liver blood supply) and
hepatic artery (25 to 30% of blood supply),
iv) a mean haematocrit of 0.50 (33), and
v) a plasma volume of 0.025 to 0.045 l/kg body weight (34)
corresponding to a total body (70 kg) plasma volume of about
2.51.
Statistical methods
Differences between groups were tested with the Mann-Whit-
ney- Wilcoxon U-test; p < 0.05 was considered to be stätisticaily
signiflcant. Correlations are described with Spearmari's rank
correlation coefficient (fs) (35).
Results
Concentrations of Iaminin and procollagen
peptide in hepatic vein and cubital vein of
patients with chronic liver diseases
The mean serum Iaminin concentrations in hepatic
(1.84 kU/1) and cubital (1.68 kU/1) vein of all patients
with chronic liver diseases % were significantly (p
»;
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< 0.001) elevated if compared with the reference
concentration of the glycoprotein in cubital vein
(0.81-1.43 kU/1) (tab. 1). In both vascular regions
the concentrations of laminin were found to be higher
in cirrhotic subjects than in patients with mere liver
fibrosis (tab. 1). Qualitatively similar results were
obtained for the procollagen peptide; the mean con-
centrations of this peptide in hepatic and cubital vein
of cirrhotic patients were higher than those measured
in liver fibrotic individuals (tab. 2). The mean procol-
lagen peptide concentrations in hepatic (28.0 §/1)
and in cubital (20.4 g/l) vein of the total population
of patients were greatly elevated compared with the
reference ränge (2—12 g/l) of the procollagen frag-
ment in serum.
There was a significant correlation (p < 0.001) be-
tween the concentrations of the respective proteins
in hepatic vein and cubital vein, but the correlation
for procollagen peptide (rs 0.734) was lower than that
for laminin (rs 0.93) (figs. l, 2). A weak (rs 0.446) but
still significant statistical relation (p < 0.001) was
observed between the concentrations of laminin and
procollagen peptide in hepatic vein (Fig. 3).
In the majority of patients with chronic liver diseases
the concentrations of laminin and procollagen pep-
tide were found to be higher in the hepatic vein than
in the peripheral vascuiar region (tab. 3). Fractions
of only 0.18 and 0.27 of all patients with chronic liver
diseases had concentrations of laminin and procolla-
gen peptide, respectively, in the hepatic vein which
were equal to or lower than those in the cubital
vein (tab. 3). The fractions of positive and negative
hepatic-cubital venous concentration differences of
both matrix proteins varied slightly between the dif-
ferent groups of liver diseases (tab. 3). The frequency
distribution of the quantitative differences of the la-
minin and procollagen peptide concentrations, re-
spectively, between hepatic and cubital vein is shown
Tab. 1. Serum concentrations (mean values ± S.D.) of laminin in cubital and hepatic vein and estimates of the synthesis/
! secretion rates by the liver in the various groups of chronic liver diseases. The estimations of the synthesis rates are based
i on several assumptions described in materials and methods. n. s. = not significant.

































































Tab. 2. Serum concentrations (mean välües ± S.D.) pf procollagen peptide in cubital and hepatic vein and estimates of the
synthesis/secretion rates by the liver in the varipus groups pf chronic liver diseases. The estimations of the synthesis rates
are based on several assuüxptions described in materials and methods. n. s. = not significant
Group pf liver diseases Number Serum procollagen peptide concentration
of patients cubital vein
(Qvf









18.2 ± 10.4 24.6 ± 16.5 6.4 ± 11.5 4.8
p < 0.03
20.8 ± 9.6 27.2 ± 15.1 6.4 ±11.5 4.8
n. s.
23.9 + 9.2 34.5 ± 14.8 10.6 ± 8.1 8.0
p < 0.005
20.4 ± 10.1 28.0 ± 16.0 7.6 ± 10.6 5.7
p < 0.001
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Fig. l. Correlation of the serum concentrations of procollagen
peptide between hepatic vein and cubital vein in all
patients with chronic liver diseases (n = 93). Spear-
marfs rank correlation coefiflcient: rs = 0.734 (p
< O.OOJ).
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Fig. 3. Scatter plot of the serum concentrations of procollagen
peptide and laminin in hepatic vein of all patients with
chronic liver diseases (n = 93). Spearmarfs rank corre^
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Fig. 2. Correlation of the serum concentrations of laminin be-
tween hepatic vein and cubital vein in all patients with
chronic liver diseases (n = 173). Spearman's rank corre-
lation coefficient: rs = 0.93 (p < 0.001).
in figure 4. It is demonstrated that about half of the
patients had eoncentrations of laminin in the hepatic
vein, which were 10 to 20% higher than those in the
cubital vein. Larger regional concentration differ-
ences were observed more frequently for procollagen
peptide than for laminin, but negative concentration
differences f laminin occurred less frequently than
those of procollagen peptide (fig. 4).
Tab. 3. Frequency distrib tion (fraction of total) of positive
and negative differences between the serum concentra-
tions of laminin and procollagen peptide (P-IIk-P) in
hepatic vein and cubital vein in patients of various
groups of liver diseases.





imimn P-III-P laminin P4II-P
Unspecified histo- 0.13 ^0.32 0.87 0.68
logy
Fibrosis 0.22 0.29 0.78 0.71
Cirrhosis 0.24 0.17 0.76 0.83














^ I m. mΟ.Θ 0.9 1.0 1.1 1.2 1.3 1.4 1.5Chepo1ic vein
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16 1.7
Fig. 4. Frequency of the relative differences AC of the coneen-
trations of laminin (n = 173; D) and prqcollagen pep-
tide (n = 93; D) in serum fr m the hepatic vein and
cubital vein in all patients with chronic liver diseases.
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The hepatic-cubital venous concentration differences
of laminin and procollagen peptide in cirrhotic
patients were higher than those found in liver fibrotic
subjects (tabs. l, 2). In fibrotic patients, the concen-
tration differences of both proteins were statistically
non-significant; the same was true for laminin in liver
cirrhotic subjects. In all patients with chronic liver
diseases the mean concentration differences of lami-
nin and of procollagen peptide were found to be 0.16
kU/1 (p < 0.02) and 7.6 μg/l (p < 0.001), respectively,
but a large statistical Variation was noted. The largest
regional concentration differences observed for lami-
nin and procollagen peptide were l .59 kU/1 and 37.4
μΐ*/1, respectively, both being measured in liver
cirrhotic patients. There was a weak but significant
correlation between the hepatic-cubital venous con-
centration differences of procollagen peptide and la-
minin (rs 0.312, p < 0.001). The regional concentra-
tion differences were not correlated with the aetiology
of the chronic liver disease, the portal venous pres-
sure, or the stages of oesophageal varices; there was
also no correlation with a number of routine clinical-
chemical liver parameters (aspartate and alanine ami-
notransferases, γ-glutamyl-transferase, bilirubin)
(data not shown).
Estimation of the production rates of serum
laminin and procollagen peptide in fibrotic
and cirrhotic livers
Based on the above described assumptions, the net
production (synthesis and/or secretion) rates of
120U -min"1 for laminin and 5.7 μg -min"1 for
procollagen peptide were calculated for the total
pop lation of patient$ with chronic liver diseases.
These values were slightly higher in cirrhotic and
lower in liver fibrotic subjects (tabs. l, 2). The chroni-
cally injured liver would therefpre be able to produce
the 4200 U of laminin present in the total body
plasma volume of 2.51 (calculated fr m the mean
concentration in the cubital vein) in about 35 min;
this time would be longer for fibrotic (79 min) and
shorter for cirrhotic livers (29 min). Similarly, the
total plasma pool of procollagen peptide of 51 μg
would be f eplenished by the chronically injured liver
in ab ut 9 min; a slightiy longer time (l l min) would
be requjred by fibrotie and a shorter time (6.4 min)
by cirrhotic livers.
Discussion
It is well established by quantitative biochemical data
and iinmunofluorescence (-peroxidase) staining
methods that in chronically injured liver an excessive
intercellular depesition of collagens (36—42) and of
laminin (43, 44) occurs. Type III collagen is distri-
buted uniformly within the lobulus and is present in
the space of Disse and around the central vein (45).
Laminin, which is a main constituent of all basement
membranes (18,19), is normally (almost) absent from
the Disse space (43, 46). In alcoholic liver injury,
however, laminin appears in the Disse space, where
it can be intensely stained by immunologic methods,
together with the light and electron microscopic ap-
pearance of basement membranes beneath the endo-
thelial cell layer of the sinusoid (43, 44, 47). The
accumulation of the matrix proteins in fibrotic liver
is brought about by their stimulated synthesis and
secretion in some sinusoidal types of liver cells (e. g.
fat-storing cells, endothelial cells) (48) but recent find-
ings point to parenchymal liver cells (hepatocytes) s
additional sources of collagen production in the liver
(42, 49 — 57). It is conceivable that during the process
of intercellular deposition of newly formed laminin
and procollagen peptide, fractions of the respective
proteins escape into the circulation, thereby contri-
buting to elevated concentrations in the liver outflow.
In accordance with this hypothesis it is shown in the
present study that the mean concentrations of laminin
and procollagen peptide in the serum of the liver
outflow vascular region are respectively 9.5% and
37.2%, higher than those in a peripheral vein. Similar
regional differences in the concentrations of these
proteins were also observed in a preliminary study
with a limited number of patients (23). Assuming
liver inflow concentrations (similar in portal vein and
hepatic artery) of laminin and procollagen peptide
identical with those measured in the systemic circula-
tion, we conclude from these data that the fibrosing
liver secretes a significant fraction of serum laminin
and procollagen peptide. It cannot be decided
whether this secretion is due t a fraction of newly
synthesized matrix proteins escaping into the blood
stream before deposition in the lobulus or to dis-
charge of matrix protein (fragments) during break-
down of hepatic connective tissue and tissue remodel-
ing. The latter possibility might be not a remote
alternative since it was shown that type III procolla-
gen can be deposited extracellularly without prior
cleavage of the aminoterminal extension peptide
(58 — 60). Thus, elevation of the procollagen peptide
in serum, although mainly a split product of the
maturation pathway of collagen (61) does not neces-
sarily reflect increased de novo synthesis of this type
of collagen, but may originale from the degradation
of tissue procollagen present in extracellular fibrils
(62, 63). The heterogeneity of aminoterminal pro-
peptide-related antigens in human serum might be
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accomplished by the different origins and pathways
of the propeptide (62—64). The weak correlations
between the concentrations and concentration differ-
ences of Iaminin and procollagen peptide indicate
that the above described mechanisms of their relative
elevations in the hepatic vein are likely to be different.
On the basis of our assumptions, the data do not
point to an impairment of clearance functions of the
fibrotic liver äs a cause of raised matrix protein levels
in serum; if this were the case, a relative decrease of
the respective concentrations in hepatic vein would
be anticipated. The latter mechanism was held re-
sponsible for the significant elevation of the hyal-
uronate concentration in the serum of cirrhotic and
fibrotic liver patients (65, 66). In fact, the concentra-
tions of hyaluronate in hepatic vein were found to
be significantly lower than those in other vascular
beds in man, which allowed the calculation of a net
hepato-splanchnic clearance of this connective tissue
compound of 0.250 l/min (67). Elucidation of the role
of the liver in the clearance of Iaminin and procolla-
gen peptide would require the determination of their
concentrations selectively in the hepatic artery and
portal vein; for obvious reasons this would present
insurmountable difficulties.
Calculation of the production rates of the serum
fractions of Iaminin and procollagen peptide in
human fibrotic liver from the present data must be
preliminary. The results may, in fact, be erroneous,
because the actual liver inflow concentrations of both
proteins cannot be measured, the levels of procolla-
gen peptide and Iaminin in the portal vein (which
contributes about 75% of total hepatic blood flow)
and the hepatic artery (which provides the remaining
25% (68)) could be different, and the blood perfusion
rates of normal liver (32) applied here might be not
valid for fibrotic livers. Keeping in mind these serious
limitations, the estiinates of relatively high produc-
tion rates would imply a rather active turnover of the
matrix proteins in the circulation, which Supports
results of a previous report suggesting a fast catabol-
ism of circulating aminopropeptide even in healthy
humans (69). The half-lives of circulating Iaminin and
procollagen peptide deduced from our data are in the
same order of magnitude äs those of hyaluronate,
which were estimated to be 5.8 min (67) ahd 2.7 min
(70) in non-liver diseased persons and about 28 min
in patients with primary biliary cirrhösis (70). Inter-
estingly, the production rates of both Iaminin and
procollagen peptide were found to be higher in
cirrhotic subjects than in patients with mere liver
fibrosis, an pbservation, which might have a iiumber
of äs yet speculative pathobiochemical explanations.
Because it is unlikely that the liver is the only source
of Iaminin and procollagen peptide in seruxn, the
catabolic and/or elimination rates of these proteins
could be even higher than those deduced from our
data. Presently, the mechanisms and organs partici-
pating in the elimination of circulating procollagen
peptide and Iaminin are not known. A low mölecular
weight fraction of procollagen peptide is eliminated
with the ürine (69, 71) but Iaminin (Mr ~ l · 1 6)
and its pepsin-resistant fragment Pl (MT 0.25 — 0.44 ·
l O6) (72), which might occur in the blood stream
(20, 21), do not pass the glomerülar membrane. As
mentioned above a clearance function of the liver for
both proteins cannot be strictly rüled out by our data
because their iminediate liver proximal concentra-
tions are not known. Although the present study
Supports the view of the fibrotic liver äs the active
producing organ of a significant fraction of serum
Iaminin and procollagen peptide, it is obvious that
more detailed Information is needed before definite
conelusions can be drawn on its role in the händling
of circulating matrix proteins.
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